A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with ...

Cassie A. Gray, MS, RN, OCN, CHPN, explains how early palliative care integration benefits patients with advanced cancer.

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

The use of ctDNA after surgery can provide guidance to patients who may be receiving input on treatment decisions from every ...

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...

Supportive oncology interventions provide a comprehensive approach to oncology, addressing patients’ needs holistically, which start with understanding a patient’s baseline ne ...

C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– ...

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.